Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Fred Hutchinson Cancer Center

Sites in Seattle, WA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 3:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
593
Shown on this page
12
Current sort
Recently updated
Campus scope
Fred Hutchinson Cancer Center, Seattle, WA
Additional filters apply within this campus.

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

Filter and sort this campus

These controls apply only within Fred Hutchinson Cancer Center, Seattle, WA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 241–252 of 593 matching trials with a site at Fred Hutchinson Cancer Center, Seattle, WA.
Indexed local directory records.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Stored official records

Not yet recruiting Phase 1 Interventional

IL-18 Armored STEAP1 CAR T Cells for the Treatment of Metastatic Castration Resistant Prostate Cancer

NCT07803653
Site status not listed — check the official record
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Antiandrogen Therapy, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Cyclophosphamide, Echocardiography Test, FH-STEAP1 IL-18 CAR T cells, Fludarabine, Leukapheresis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography
Drug · Procedure · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2044
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Sep 15, 2026, 10:32 AM EDT
Active, not recruiting Phase 1 Interventional

Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer

NCT06555796
Site status not listed — check the official record
View directory record Official record
Conditions
High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer, High-risk Biochemical Recurrence, Non-metastatic Castration-sensitive Prostate Cancer, Prostate Cancer
Interventions
Xaluritamig
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
8
States / cities
Minneapolis, Minnesota • New York, New York • Chapel Hill, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 14, 2026, 8:41 PM EDT
Active, not recruiting Phase 3 Interventional

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

NCT05204927
Site status not listed — check the official record
View directory record Official record
Conditions
Metastasis From Malignant Tumor of Prostate
Interventions
177Lu-PSMA-I&T, Abiraterone with Prednisone or Enzalutamide
Drug
Lead sponsor
Curium US LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
37
States / cities
Tucson, Arizona • Fullerton, California • Long Beach, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 3, 2026, 8:03 PM EDT
Active, not recruiting Not applicable Interventional Results available

Quit2Heal Smartphone App in Helping Cancer Patients Quit Smoking

NCT04409236
Site status not listed — check the official record
View directory record Official record
Conditions
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Interventions
Quit2Heal, QuitGuide, Survey Administration
Behavioral · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 16, 2026, 5:33 AM EDT
Active, not recruiting Phase 3 Interventional

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

NCT04340141
Site status not listed — check the official record
View directory record Official record
Conditions
Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8
Interventions
Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Oxaliplatin, Questionnaire Administration, Resection
Drug · Other · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
441
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 325 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 13, 2026, 4:45 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

NCT03386513
Site status not listed — check the official record
View directory record Official record
Conditions
Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm
Interventions
IMGN632
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
16
States / cities
Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 16, 2026, 12:19 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)

NCT07285694
Site status not listed — check the official record
View directory record Official record
Conditions
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions
AB-3028
Biological
Lead sponsor
Arsenal Biosciences, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
9
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 16, 2026, 6:08 AM EDT
Recruiting Phase 1 Interventional

OM336 in Autoimmune Cytopenias

NCT07083960
Status at this site: Recruiting
View directory record Official record
Conditions
AIHA - Cold Autoimmune Hemolytic Anemia, AIHA - Warm Autoimmune Hemolytic Anemia, ITP - Immune Thrombocytopenia
Interventions
OM336
Drug
Lead sponsor
Lakefront Biotherapeutics West LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Duarte, California • Washington D.C., District of Columbia • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 16, 2026, 12:32 AM EDT
Recruiting Not applicable Interventional

A Study of Time-Restricted Eating in Childhood Cancer Survivors

NCT07009288
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Childhood Cancer Survivors
Interventions
Calls, Children's Oncology Group Heart Health Link, Dried blood spot, Fasting, Monthly weights, Participant Questionnaires
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
4
States / cities
New York, New York • Memphis, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 14, 2026, 11:23 PM EDT
Recruiting Phase 1 Interventional

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

NCT06343402
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced Lung Carcinoma, KRAS G12C, Metastatic Lung Cancer, Metastatic Non-Small Cell Lung Cancer, NSCLC, Non-small Cell Lung Cancer
Interventions
BBO-10203, BBO-8520, Pembrolizumab
Drug
Lead sponsor
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
23
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 14, 2026, 10:49 PM EDT
Active, not recruiting Phase 1 Interventional

AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

NCT05617755
Site status not listed — check the official record
View directory record Official record
Conditions
Abdominal Neoplasm, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Genital Neoplasm, Female, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence
Interventions
AB-1015
Biological
Lead sponsor
Arsenal Biosciences, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 17, 2026, 3:09 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

A Novel Smartphone Application for Helping Teens Stop Vaping, QuitQuest Vaping R01

NCT07739706
Site status not listed — check the official record
View directory record Official record
Conditions
Tobacco-Related Carcinoma
Interventions
Interview, Smartphone Application-based Intervention, Survey Administration
Other · Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
13 Years to 17 Years
Enrollment
1,072 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 14, 2026, 11:09 AM EDT

About this Fred Hutchinson Cancer Center institution page

What this page lists
ClinicalTrials.gov records that list Fred Hutchinson Cancer Center in Seattle, WA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.